Abstract:ObjectiveTo investigate the value of combined measurement of alpha-fetoprotein (AFP) and AFP-L3% in the diagnosis of hepatocellular carcinoma (HCC). MethodsA retrospective analysis was performed for serological parameters and clinical data of 1208 patients with chronic hepatitis, 1967 patients with liver cirrhosis, and 1569 patients with primary HCC who attended The Fifth Medical Center of Chinese PLA General Hospital from January 2010 to December 2017. The distribution of serum AFP and AFP-L3% was analyzed, and AFP alone, AFP-L3% alone, and AFP combined with AFP-L3% were compared in terms of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC). The correlation of AFP with AFP-L3 level and AFP-L3% was also analyzed. A one-way analysis of variance or the Kruskal-Wallis H test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. The Spearman rank correlation test was used for correlation analysis of continuous data, the Delong test was used for comparison of AUC, and logistic regression was used to establish the model of AFP combined with AFP-L3% for the diagnosis of HCC. ResultsThe HCC group had significantly higher serum levels of AFP and AFP-L3 than the liver cirrhosis group and the chronic hepatitis group (H=1107.3 and 1076.9, both P＜0.01). The HCC group had a significantly higher positive rate of AFP-L3% than the liver cirrhosis group and the chronic hepatitis group (30.9% vs 3.0%/2.8%, P＜0.01). The HCC group had a significantly higher level of AFP-L3 than the liver cirrhosis group and the chronic hepatitis group （3.3(0-13.4)% vs 0/0, H=1034.1, P＜001）. The correlation analysis showed that serum AFP was significantly correlated with AFP-L3 level (r=0.91, P＜0.01), and there was no correlation between AFP-L3% and AFP (r=0.04, P＞0.05). With specificity remaining the same, AFP combined with AFP-L3% had a significantly higher sensitivity in the diagnosis of HCC than AFP alone (26.6% vs 18.4%, P＜0.01) or AFP-L3% alone (36.6% vs 30.9%, P＜0.01). The subgroup analysis showed that for the samples with AFP ≥10 μg/L, AFP combined with AFP-L3% had a significantly higher AUC in the diagnosis of HCC than AFP alone (0.745 vs 0.701, P＜0.01); for the tumor with a diameter of ＞2 cm or hepatitis B-related liver cancer, AFP combined with AFP-L3% had a significantly higher sensitivity than AFP alone (27.6% vs 180%/27.7% vs 19.1%, both P＜0.01) or AFP-L3% alone (37.0% vs 30.3%/36.9% vs 31.8%, both P＜0.01). For the group with a tumor diameter of ≤2 cm and the group without hepatitis B-related liver cancer, there was no significant difference in sensitivity between AFP combined with AFP-L3% and AFP or AFP-L3% alone in the diagnosis of HCC (all P＞0.05). ConclusionAFP combined with AFP-L3% can significantly improve the sensitivity of HCC diagnosis and has a good clinical value in the diagnosis of hepatitis B-related liver cancer and liver cancer with a tumor diameter of ＞2 cm.

Advancement in researches of typical marker of AFP for diagnosis and treatment of liver cancer

The Current Status and Future Prospects of Laboratory Biomarkers in the Diagnosis of Liver Cancer

New Blood Biomarkers for the Diagnosis of AFP-Negative Hepatocellular Carcinoma

Alpha-fetoprotein: Past, present, and future

Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma

Α-Fetoprotein Mrna Detection in Peripheral Blood and Bone Marrow in Patients with Hepatocellular Carcinoma and Its Sigificance

The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma

Biology and significance of alpha‐fetoprotein in hepatocellular carcinoma

Early Alpha-Fetoprotein Response Predicts Treatment Efficacy of Antiangiogenic Systemic Therapy in Patients with Advanced Hepatocellular Carcinoma.

The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma

Early Alpha‐foetoprotein Response Associated with Treatment Efficacy of Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma

Value of combined measurement of alpha-fetoprotein and alpha-fetoprotein L3％in the diagnosis of hepatocellular carcinoma

Detection of AFP Mrna in Peripheral Blood of Patients with Hepatocellular Carcinoma and Its Significance

Serological Diagnosis of Hepatocellular Carcinoma: Challenges and Opportunities

Alpha-fetoprotein Still is a Valuable Diagnostic and Prognosis Predicting Biomarker in Hepatitis B Virus Infection-Related Hepatocellular Carcinoma.

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

[Application of Alpha-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma].

Clinical significance of alpha-fetoprotein detection in HBV infectious related diseases

Intramolecular Fluorescence Resonance Energy Transfer Strategy for Accurate Detection of AFP-L3% and Improved Diagnosis of Hepatocellular Carcinoma

Elevated Serum Alpha Fetoprotein Levels Promote Pathological Progression of Hepatocellular Carcinoma